HR 796 Re-checks Congress.gov for new actions and updates the bill's status, and fills in any sponsors, committees, or related bills that are missing. It does not re-pull sponsors/cosponsors/committees/related — those rarely change — and it skips all work if nothing has changed upstream, so it's cheap to click.
To amend the Federal Food, Drug, and Cosmetic Act to require a warning label advising that the effects of mifepristone can be counteracted, to amend the Public Health Service Act to establish a hotline to provide information to women seeking to counteract the effects of mifepristone, and for other purposes.
Summary
The Second Chance for Moms Act of 2025 amends the Federal Food, Drug, and Cosmetic Act to require mifepristone labeling to include a warning statement indicating that the effects of mifepristone can potentially be counteracted by natural progesterone and directing users to contact a specified hotline for more information. The bill requires the warning label to be printed in conspicuous text and takes effect six months after enactment. The bill also amends the Public Health Service Act to require the Secretary of Health and Human Services to establish or maintain a toll-free hotline available 24 hours a day, seven days a week, to provide support for women seeking to reverse the effects of mifepristone. Referrals through the hotline may only be made to health care providers that offer abortion pill reversal services.
AI-generated plain-language summary of the bill text — neutral, and may be imperfect. See the full text below for the exact wording.
Sponsor (1)
13 cosponsors
- Rep. Babin, Brian [R-TX-36] (R-TX)
- Rep. Biggs, Sheri [R-SC-3] (R-SC)
- Rep. Clyde, Andrew S. [R-GA-9] (R-GA)
- Rep. Harris, Andy [R-MD-1] (R-MD)
- Rep. Harris, Mark [R-NC-8] (R-NC)
- Rep. Moore, Barry [R-AL-1] (R-AL)
- Rep. Moore, Riley [R-WV-2] (R-WV)
- Rep. Ogles, Andrew [R-TN-5] (R-TN)
- Rep. Palmer, Gary J. [R-AL-6] (R-AL)
- Rep. Rose, John W. [R-TN-6] (R-TN)
- Rep. Tenney, Claudia [R-NY-24] (R-NY)
- Rep. Weber, Randy K. Sr. [R-TX-14] (R-TX)
- Rep. Webster, Daniel [R-FL-11] (R-FL)
Money behind the sponsor
Top reported contributors to Mary E. Miller’s campaign committee (2024 cycle) — who funds the bill’s sponsor, not a claim about this bill. Data from FEC.
- NULL $22,349
- SAULSBURY INDUSTRIES $13,200
- THOMPSON THRIFT DEVELOPMENT $11,600
- KASPAR LAW COMPANY $6,600
- INDECK ENERGY SERVICES $6,600
Organizations whose employees gave the most — itemized individual contributions grouped by the donor’s reported employer (FEC Schedule A). Full finance for Mary E. Miller → · Outside spending →
Actions (2)
- Jan 28, 2025 Referred to the House Committee on Energy and Commerce. · house
- Jan 28, 2025 Introduced in House
Similar bills (6)
Bills with similar text or summary — includes reintroductions across Congresses. Ranked by semantic similarity of the bill text (computed locally); a neutral discovery aid, not a claim the bills are duplicates.
Full text
IN THE HOUSE OF REPRESENTATIVES
January 28, 2025
Mrs. Miller of Illinois (for herself, Mr. Babin, Mr. Moore of Alabama, Mr. Moore of West Virginia, Mr. Ogles, Mr. Webster of Florida, Ms. Tenney, Mr. Clyde, Mr. Harris of Maryland, and Mr. Weber of Texas) introduced the following bill; which was referred to the Committee on Energy and Commerce
A BILL
To amend the Federal Food, Drug, and Cosmetic Act to require a warning label advising that the effects of mifepristone can be counteracted, to amend the Public Health Service Act to establish a hotline to provide information to women seeking to counteract the effects of mifepristone, and for other purposes.
Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the “Second Chance for Moms Act of 2025”.
SEC. 2. MIFEPRISTONE WARNING LABEL AND HOTLINE.
(a) Warning Label.—
(1) In general.—Section 502 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 352) is amended by adding at the end the following: “(hh) If it is the drug mifepristone, and its labeling does not bear the following statement printed in conspicuous text: ‘WARNING: Medical evidence suggests that the abortifacient effects of mifepristone can be counteracted by natural progesterone, which can increase the chance of fetal survival. The American Society for Reproductive Medicine has determined that natural progesterone is safe in the first trimester of pregnancy. For more information, call [___].’ (with the blank filled in to refer to the appropriate number for the hotline under section 1009 of the Public Health Service Act).”.
(2) Effective date.—Section 502(hh) of the Federal Food, Drug, and Cosmetic Act (as added by paragraph (1)) applies beginning on the date that is 6 months after the date of enactment of this Act.
(b) Hotline.—Title X of the Public Health Service Act (42 U.S.C. 300 et seq.) is amended by adding at the end the following:
“SEC. 1009. HOTLINE FOR REVERSAL OF EFFECTS OF MIFEPRISTONE.
“(a) In General.—The Secretary shall establish or maintain, directly or by grant or contract, a toll-free hotline to provide support for 24 hours a day, 7 days a week, for women seeking to reverse the effects of the drug mifepristone.
“(b) Referrals to APR Providers Only.—A referral through the hotline described in subsection (a) may only be made to a health care provider that provides abortion pill reversal services.”. <all>
Comments